Page updated ·next FDA decision on the calendar·Data as of Nov 19, 2026 12:24 AM ET
NDA 220415 is the FDA application for JUVMO (tavapadon). The FDA's Orange Book lists the applicant of record as ABBVIE INC and the first approval on it as Sep 25, 2026. Owner today: AbbVie Inc. (NYSE: ABBV).
“AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Cerevel Therapeutics (NASDAQ: CERE).” … “Tavapadon, a first-in-class dopamine D1/D5 selective partial agonist for the management of Parkinson's disease”
Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.
Facts only; not investment advice. The FDA facts on this page are read from the FDA
Orange Book data files; every other name links the company document or SEC filing it comes from.
pdufa.bio is not affiliated with the FDA.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.